

Code No. 10357

## Anti-Human

## C-ERC/Mesothelin (22A31) Mouse IgG MoAb

Volume : 100 µg

Introduction: Erc has been identified as a gene showing stronger expression in cancer-affected renal cell than in normal renal tissue in Eker rats (a rat model of renal cancer). The human homologue of the protein encoded by this gene is called MPF (megakaryocyte potentiating factor) or mesothelin. This protein is detected especially prominently in mesothelial cells, and its involvement has been suggested in the development of mesothelioma, making it a promising tumor marker. In humans, involvement of this protein has also been suggested in the development of pancreatic, ovarian and pulmonary cancers, etc. The protein is expressed as a GPI anchor-type membranous protein (about 71 kDa in molecular weight), which is thought to be digested by a furin-like protease to yield fragments about 31 kDa and 40 kDa in size.

We have prepared an antibody specific to C-ERC/Mesothelin (40 kDa fragment).

: Recombinant protein for Human C-ERC/Mesothelin Antigen

Source : Mouse-Mouse hybridoma

(X63 - Ag 8.653 x BALB/c mouse spleen cells, ascites)

Clone : 22A31

Purification : Affinity purified with Protein A

**Form** : Lyophilized product from 1% BSA in PBS containing 0.05% NaN<sub>3</sub>

How to use : 1.0 mL deionized water will be added to the product, then its concentration comes to

100 µg/mL

**Stability** : Lyophilized product, 5 years at 2 - 8 °C

: Solution, 2 years at -20 °C

: This antibody can be stained in formalin fixed paraffin embedded tissues after micro Application

> wave treatment by several Immunohistochemical techniques such as Avidin Biotin Complex (ABC) Method. The optimal dilution is 1-5 µg/mL, however, the dilution

rate should be optimized by each laboratories.

: This antibody can be used for western blotting in concentration of 1-2 µg/mL

: This antibody can be used for flow cytometry analysis in concentration of 1-2 µg/mL

: 1. Establishment of novel mAb to human ERC/mesothelin useful for study and Reference

diagnosis of ERC/mesothelin-expressing cancers.

Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M, Hino O. Pathol Int. 2009 Mar;59(3):161-6. doi: 10.1111/j.1440-1827.2009.02344.x.

PMID: 19261093

2. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo. Inami K, Abe M, Takeda K, Hagiwara Y, Maeda M, Segawa T, Suyama

M.Watanabe S. Hino O.

Cancer Sci. 2010 Apr;101(4):969-74. doi: 10.1111/j.1349-7006.2009.01463.x.

Epub 2009 Dec 9.PMID: 20100205